William Monaco, MD
Internal Medicine · Lebanon, NHNPI 1346683240
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $66,013 of the $96,710 with a category attached, or 68.3%. AbbVie accounts for 78.9% of it on its own, with 22 other manufacturers making up the rest. 2025 is the largest year on record at $32,711, more than ten times the $848 reported in 2019. Among internal medicine clinicians in NH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 645 payments — averaging $149.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$76K
- UCB, Inc.$14K
- Amgen$2K
- GSK$876
- Lilly USA, LLC$634
- Sanofi$593
- plus $2K from 17 others
What the payments were for
- Consulting fees$9,88510%
- Speaking & faculty fees$66,01368%
- Travel & lodging$8,6669%
- Food & beverage$11,88312%
- Education$2630%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 251 | $76,319 |
| UCB, Inc. | 68 | $14,347 |
| Amgen(2 entities) | 116 | $1,550 |
| GSK | 48 | $876 |
| Lilly USA, LLC | 29 | $634 |
| Sanofi | 22 | $593 |
| Johnson & Johnson | 15 | $538 |
| E.r. Squibb & Sons, L.L.C. | 19 | $337 |
| AstraZeneca | 18 | $333 |
| Pfizer | 15 | $292 |
| Mallinckrodt Hospital Products Inc. | 9 | $257 |
| Genentech USA, Inc. | 7 | $126 |
| Organon | 5 | $87 |
| Novartis | 5 | $74 |
| Aurinia Pharma U.S., Inc. | 4 | $64 |
| Merck | 4 | $57 |
| Radius Health, Inc. | 2 | $48 |
| Boehringer Ingelheim | 2 | $46 |
| Genentech, Inc. | 1 | $38 |
| Mallinckrodt Enterprises LLC | 2 | $36 |
| Recordati_rare_diseases_inc. | 1 | $27 |
| Sobi, Inc | 1 | $16 |
| Sandoz | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$96,710 in reported general payments places this provider in the 95th percentile of 504 internal medicine providers in New Hampshire.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 80 | $681,044 |
| Skyrizi PenRisankizumab-Rzaa | 32 | $665,959 |
| RinvoqUpadacitinib | 51 | $387,494 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 37 | $344,469 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 20 | $288,092 |
| Actemra ActpenTocilizumab | 61 | $282,532 |
| OrenciaAbatacept | 43 | $246,529 |
| Enbrel MiniEtanercept | 29 | $210,076 |
| Xeljanz XrTofacitinib Citrate | 22 | $172,085 |
| TremfyaGuselkumab | 12 | $167,959 |
| Enbrel SureclickEtanercept | 20 | $153,553 |
| Orencia ClickjectAbatacept | 13 | $135,743 |
| OtezlaApremilast | 23 | $108,094 |
| EnbrelEtanercept | 12 | $94,159 |
| KevzaraSarilumab | 18 | $92,537 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq | $76,319 | $387,49451 claims |
| E.r. Squibb & Sons, L.L.C.Orencia | $337 | $246,52943 claims |
| AmgenOtezla, Enbrel | $1,550 | $202,25335 claims |
| Johnson & JohnsonTremfya | $538 | $167,95912 claims |
| SanofiKevzara | $593 | $92,53718 claims |
| Lilly USA, LLCOlumiant | $634 | $29,52311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 504 internal medicine providers in New Hampshire.
Other internal medicine in Lebanon
- Deborah TepperLebanon$133K
- Mary McGowanLebanon$26K
- Daniel FeldmanLebanon$17K
- Amir Soheil TolebeyanLebanon$13K
- Scott RizziLebanon$13K
- Jonathan LurieLebanon$8K
- Lisa AdamsLebanon$4K
- Julia LakeLebanon$3K
- Stephen LiuLebanon$2K
- Lionel LewisLebanon$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.